MYX mayne pharma group limited

NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales...

  1. 1,060 Posts.
    lightbulb Created with Sketch. 86
    NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.01
Change
0.005(0.10%)
Mkt cap ! $409.4M
Open High Low Value Volume
$5.05 $5.09 $4.96 $227.6K 45.27K

Buyers (Bids)

No. Vol. Price($)
2 250 $4.99
 

Sellers (Offers)

Price($) Vol. No.
$5.02 194 6
View Market Depth
Last trade - 11.40am 25/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.